Hemostatic defects in cancer patients

Cancer Investigation

Volumn 15, Issue 1, 1997, Pages 23-36

  Kempin, Sanford J ^a,b  

^a Desert Hosp Compreh Cancer Center   (United States)

^b Salick Health Care Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING DISORDER; CANCER; CANCER PATIENT; ENDOTHELIUM CELL; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031015786     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709018914     Document Type: Review

References (213)

1. Trousseau A: Phlegmasia alba dolens. Clinique Medicale de l'Hotel Dieu de Paris, The New Sydenham Society, London, England, 3:94, 1865.
2. Friedreich N: Ein neuer Fall von Leukämie. Arch Pathol Anat 12:37, 1857.
3. Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517-522, 1994.
4. Rodker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917, 1995.
5. Lollar, Owen WC: Clearance of thrombin from circulation in rabbits by high affinity binding sites on endothelial: possible role in the inactivation of thrombin by antithrombin III. J Clin Invest 66:1222-1230, 1980.
6. Belt RJ, Leite C, Haas CD, et al: Incidence of hemorrhagic complications in patients with cancer. JAMA 239:2571-2574, 1978.
7. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983.
8. Connolly DT, Heuvelman DM, Nelson R, et al: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470, 1989.
9. Cohen PS, O'Brien TF, Schoenbaum SC, et al: The risk of endothelial infection in adults with salmonella bacteremia. Ann Intern Med 89:931-932, 1978.
10. McGrath JM, Stewart GJ: The effects of endotoxin on vascular endothelium. J Exp Med 129:883-948, 1968.
11. Remick DG, Streiter RM, Eskandari MK, et al: Role of tumor necrosis factor-α in lipopolysaccharide-induced pathologic alterations. Am J Pathol 136:49-60, 1990.
12. Luscinkas FW, Brock AF, Arnont MA, et al: Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte(CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol 142:2257-2263, 1989.
13. Strieter RM, Kunkel SL, Showell HJ, et al: Endothelial cell gene expression of a neutrophil chemotactic factor by TNFα, LPS and IL-IB. Science 243:1467-1469, 1989.
14. Bussolino F, Carrussi G, Baglioni C: Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1α. J Biol Chem 263:11856-11861, 1988.
15. Schleef R, Bevilacqua M, Sawdey M, et al: Cytokine activation of vascular endothelium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797-5803, 1988.
16. Nawroth P, Stern D: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740-745, 1986.
17. Moore K, Esmon C, Esmon N: Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bo vine aortic endothelial cells in culture. Blood 73:159-165, 1989.
18. Clauss M, Ryan J, Stern D: Modulation of endothelial cell hemostatic properties by TNF: Insights into the role of endothelium in the host response to inflammatory stimuli. In: Tumor Necrosis Factors: The Molecule and Their Emerging Role in Medicine, edited by B Beutler, New York, Ravin Press, 1992, pp 49-63.
19. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NV: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 79:124, 1987.
20. Van der Poll T, Buller H, Ten Cate H, et al: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622-1627, 1990.
21. Tolcher AWM, Giusti RM, O'Shaughnessy JA, Cowan KH: Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: A report of two cases. Cancer Invest 13(2):188-192, 1995.
22. Conti JA, Scher HI: Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor toxicity. Cancer 70:2699-2702, 1992.
23. Al-Mondhiry H: Disseminated intravascular coagulation: Experience in a major cancer center. Thromb Diath Hemorrh 34:181-193, 1975.
24. Murgo AJ: Thrombotic microangiopathy in the cancer patient including those induced by chemotherapy agents. Semin Hematol 24:161-177, 1987.
25. Gulati SC, Sordillo P, Kempin S, et al: Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer 45:2252-2257, 1980.
26. Licciardello JTW, Moake JL, Rudy CK, et al: Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42:296-300, 1985.
27. Walker R, Rosenblum MK, Kempin SJ, et al: Carboplastin-associated thrombotic micro-angiopathic hemolytic anemia. Cancer 64: 1017-1028, 1989.
28. Suwake A, Takahashi K, Yasni S, et al: Bleomycin-stimulated hamster alveolar macrophages release interleukin-1. Am J Pathol 132:512-520, 1988.
29. Hout AE, Hacker MP: Role of reactive nitrogen intermediate production in alveolar macrophage-mediated cytostatic activity induced by bleomycin lung damage in rats. Cancer Res 50:7863-7866, 1990.
30. Lokich JJ, Becker B: Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 52:1586-1589, 1983.
31. Anderson AJ, Krasnow SH, Boyer MW, et al: Thrombosis: The major Hickman catheter complication in patients with solid tumors. Chest 95:71-75, 1989.
32. Lokich JJ, Bothe A, Benotti P, et al: Complications and management of implanted venous access catheters. J Clin Oncol 3:710-717, 1985.
33. Fraschini G, Jadeja J, Lawson M, et al: Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol 5:672-678, 1987.
34. Bern MM, Lokich JJ, Wallach SR, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112:423-428, 1990.
35. Kyle RA, Bayrd ED: Amyloidosis: Review of 236 cases. Medicine (Baltimore) 54(4):271-299, 1975.
36. Piette WW: Myeloma, paraproteinemias, and the skin. Med Clin North Am 70:155-176, 1986.
37. Yood RAA, Skinner M, Rubinow A, et al: Bleeding manifestations in 100 patients with amyloidosis. JAMA 249:1322-1324, 1983.
38. Cordonnier D, Puglisi JC, Shaerer R, et al: Nephrotic syndrome and acquired deficiency of Stuart factor revealing the presence of amyloidosis and myeloma. J Urol Nephrol (Paris) 78:760-764, 1972.
39. Handley DA, Lawrence JR: Factor IX deficiency in the nephrotic syndrome. Lancet 1:1079-1081, 1967.
40. Furie B, Voo L, McAdam KPW, et al: Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 304:827-830, 1981.
41. Perlin E, Brakman P, Berg RS, et al: Enhanced blood coagulation and fibrinolysis in a patient with primary amyloidosis. Thromb Diath Haemorrh 26:9-14, 1971.
42. Clyne NP, Caldwell AB: Acquired alpha-2 antiplasmin deficiency secondary to amyloidosis. Thromb Haemost 58:797, 1987 (letter).
43. Francis RB JR, Liebman H, Koehler S, et al: Accelerated fibrinolysis in anyloidosis: Specific binding of tissue plasminogen activator inhibitor by an amyloidogenic monoclonal IgG (abst). Blood 68(Suppl):333A, 1986.
44. Lau SO, Tkachuck JY, Kasegawa DK, et al: Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. J Pediatr 96:390-392, 1980.
45. Lerner AB, Watson CJ: Studies of cryoglobulins; unusual purpura associated with presence of high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci 214:410-415, 1947.
46. Kasabach HS, Merritt KK: Capillary hemangioma with extensive purpura: Report of a case. Am J Dis Child 259:1063-1070, 1940.
47. Makk L, Delmore F, Creech JL, et al: Clinical and morphological features of hepatic angiosarcoma in vinyl chloride workers. Cancer 37:149-163, 1976.
48. Warrell RP Jr, Kempin SJ, Benua RS, et al: Intratumoral consumption of indium-111 labelled platelets in a patient with hemangiomalosis and intravascular coagulation (Kasabach-Merritt syndrome). Cancer 52:2256-2260, 1983.
49. Warrell RP Jr, Kempin SJ: Treatment of severe coagulopathy in the Kasabach-Merritt syndrome with aminocaproic acid and cryoprecipitate. N Engl J Med 313:309-312, 1985.
50. Ezekowitz RAB, Milliken JB, Folkman J: Interferon alfa 2α therapy for the life-threatening hemangiomas of infancy. N Engl J Med 326:1456-1463, 1992.
51. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new, significant, and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992.
52. Harker LA, Slichter SJ: The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 287:155-159, 1972.
53. Slichter SJ: Controversies in platelet transfusion therapy. Annu Rev Med 31:509-540, 1980.
54. McNiece IK, McGrath HE, Quesenberry PJ: Granulocyte colony-stimulating factor augments in vitro megakaryocyte colony formation by interleukin-3. Exp Hematol 16:807-810, 1988.
55. Asano S, Okano A, Ozawa K, et al: In vivo effects of recombinant IL-6 in primates: Stimulated production of platelets. Blood 75: 1602-1605, 1990.
56. Jackson CW: Cholinesterase as a possible marker for early cells in the megakaryocyte series. Blood 42:413, 1973.
57. Harker LA, Finch CA: Thrombokinetics in man. J Clin Invest 48:963-974, 1969.
58. Branehog I, Kutti J, Weinfeld A: Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 27:127-143, 1974.
59. Levin J, Conley CL: Thrombocytosis associated with malignant disease. Arch Intern Med 114:497-500, 1964.
60. Tranum BL, Haut A: Thrombocytosis: Platelet kinetics in neoplasia. J Lab Clin Med 84:615-619, 1974.
61. Shreiner DP, Weinberg J, Enoch D: Plasma thrombopoietic activity in humans with normal and abnormal platelet counts. Blood 56: 183-188, 1980.
62. Bellucci S, Janvier M, Tokelem G, et al: Essential thrombocythemias: Clinical, evolutionary and biological data. Cancer 58: 2440-2447, 1986.
63. Shafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1-2, 1984.
64. Kessler CM, Klein HG, Hawlik RJ: Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 50:157-167, 1982.
65. Silverstein MN, Petitt RM, Solberg LA, et al: Anagrelide: A new drug for treating thrombocytosis. N Engl J Med 318:1292-1294, 1988.
66. Giles FJ, Gray AF, Brozovic M, et al: Alpha-interferon therapy for essential thrombocythemia. Lancet 2:70-72, 1988.
67. Slater PP, Sherlock EC: Splenectomy, thrombocytosis and venous thrombosis. Ann Surg 23:145-146, 1957.
68. Hirsh J, Dacie JV: Persistent postsplenectomy thrombocytosis and thromboembolism: A consequence of continuing anemia. Br J Haematol 12:44-53, 1966.
69. Hoagland HC: Hematologic complications of cancer chemotherapy. Semin Oncol 9:95-102, 1982.
70. Hellman S, Botnick LE: Stem cell depletion: an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 2:181-184, 1977.
71. Botnick LE, Hannon EC, Hellman S: Late effects of cytotoxic agents on the normal tissues of mice. Front Radiat Ther Oncol 13:36-47, 1979.
72. Nelson DF, Chaffy JT, Hellman S: Late effects of x-irradiation on the ability of mouse bone marrow to support hematopoiesis. Int J Radiat Oncol Biol Phys 2:39-45, 1977.
73. Knospe WA, Blom J, Crosby WH: Regeneration of locally irradiated bone marrow. I. Dose dependent long term changes in the rat, with particular emphasis upon vascular and stromal reactions. Blood 28:398-415, 1966.
74. Sacks EL, Goris ML, Glatstein E, et al: Bone marrow regeneration following large field radiation: Influence of volume, age, dose, and time. Cancer 42:1057-1065, 1978.
75. Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266:905-909, 1962.
76. Djerassi I, Farber S, Evans AE: Transfused fresh platelet concentrates in patients with secondary thrombocytopenia. N Engl J Med 268:221-226, 1963.
77. Geissler K, Valent P, Bettelheim P, et al: In vitro synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 79:1155-1160, 1992.
78. Brugger W, Frisch J, Schulz G, et al: Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 10:1452-1459, 1992.
79. Burstein SA, Downs T, Friese P, et al: Thrombocytopoiesis in normal and sublethally irradiated dogs: Response to human interleukin-6. Blood 80:420-428, 1992.
80. Kim HD, Boggs DR: A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer. Am J Med 67:371-377, 1979.
81. Kempin S: Late hematologic complications after treatment of Hodgkin's disease. In: Hodgkin's Disease: The Consequences of Survival, edited by MJ Lacher and JR Redman, Philadelphia, Lea & Febiger, 1990, pp 63-111.
82. Kaden BR, Rosse WF, Hauch TW: Immune thrombocytopenia in lymphoproliferative diseases. Blood 53:545-551, 1979.
83. Carey RW, McGinnis A, Jacobson BM, et al: Idiopathic thrombocytopenic purpura complicating chronic lymphocytic leukemia: Management with sequential splenectomy and chemotherapy. Arch Intern Med 136:62-66, 1976.
84. McMillan R: Antigen-specific assays in immune thrombocytopenia. Trans Med Rev 4:136, 1990.
85. Bell WR, Royall RM: Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J Med 303:902-907, 1980.
86. Trowbridge AA, Caraveo J, Green JB III, et al: Heparin-related immune thrombocytopenia: Studies of antibody-heparin specificily. Am J Med 65:277-283, 1978.
87. Aster RR: Pooling of platelets in the spleen: Role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 45:645-657, 1966.
88. Byhardt RW, Brace KC, Wiernik PH: The role of splenic irradiation in chronic lymphocytic leukemia. Cancer 35:1621-1625, 1975.
89. Rubenstein DB, Longo DL: Peripheral destruction of platelets in chronic lymphocytic leukemia: Recognition, prognosis, therapeutic complications. Am J Med 7:729-732, 1981.
90. Vainchenkar W, Chapman J, Deschamps JF, et al: Normal human serum contains a factor(s) capable of inhibiting megakaryocyte colony formation. Exp Hematol 10:650-660, 1982.
91. Ishibashi T, Miller SL, Burstein SA: Type B transforming growth factor is a potent inhibitor of murine megakaryocytopoiesis in vitro. Blood 69:1737-1741, 1987.
92. Gewirtz AM, Calabretta B, Rucinski B, et al: Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic C-terminal PF4 peptide. J Clin Invest 83:1477-1486, 1989.
93. Dessypris EN, Gleaton JH, Sawyer ST, et al: Suppression of maturation of megakaryocyte colony forming unit in vitro by platelet released glycoprotein. J Cell Physiol 130:361-368, 1987.
94. Rao AK, Schapira M, Clements ML, et al: A prospective study of platelets and proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med 318(16):1021, 1988.
95. Ream VJ, Deykin D, Gurewich V, et al: The aggregation of human platelets by bacterial endotoxin. J Lab Clin Med 66:245-252, 1965.
96. George C, Carlet J, Sobel A, et al: Circulating immune complexes in patients with gram-negative septic shock. Int Care Med 6:123-127, 1980.
97. Kelton JC, Neame PB, Gouldie J, et al: Elevated platelet-associated IgG in the thrombocytopenia of septicemia. N Engl J Med 300:760-764, 1979.
98. Neame PB, Kelton JC, Walker JR, et al: Thrombocytopenia in septicemia: The role of disseminated intravascular coagulation. Blood 56:88-92, 1980.
99. Stuart JJ, Lewis JF: Platelet aggregation and electron microscopic studies of platelets in preleukemia. Arch Pathol Lab Med 106:458, 1982.
100. DiMinno G, Corraggio F, Cerbone AM, et al: A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 77:157-164, 1986.
101. Kasturi J, Saraya AK: Platelet functions in dysproteinemia. Acta Haematol 10:104-113, 1978.
102. McGrath KM, Stuart JJ, Richards F: Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinemia states. Br J Haematol 42:585-591, 1979.
103. Stricker RB, Wong D, Saks SR, Corash L, Shuman MA: Acquired Bernard-Soulier syndrome. J Clin Invest 76:1274, 1985.
104. Bovill EG, Ershler WB, Golden EA, et al: A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 85:115-123, 1986.
105. Bidde U, Schaefer G, Mueller N, et al: Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 64:981-985, 1984.
106. Brody JI, Haidar ME, Rossnian RE: A hemorrhagic syndrome in Waldenström's macroglobulinemia secondary to immunoadsorption of factor VIII. N Engl J Med 300:408-410, 1979.
107. DiMinno G, Cerbone A, Usberti M, et al: Platelet dysfunction in uremia. II. Corrections of arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108:246-252, 1986.
108. Bloom A, Greaves M, Preston FE, et al: Evidence against a platelet cyclooxygenase defect in uremic subjects on chronic dialysis. Br J Haematol 62:143-149, 1986.
109. Escolar G, Casa A, Bastidi E: Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76:1336-1340, 1990.
110. Carvalho AC: Acquired platelet dysfunction in patients with uremia. Hematol Oncol Clin North Am 4(1):129-143, 1990.
111. Fernandez F, Goudrable C, Sie P, et al: Low hematocrit and prolonged bleeding time in uremic patients: Effect of red cell transfusions. Br J Haematol 59:139, 1985.
112. Moia M, Mannucci PM, Vizzotto L: Improvement in the hemostatic defect of uremia after treatment with recombinant human erythropoietin. Lancet 8570:1227, 1987.
113. Janson PA, Jubelirer SJ, Weinstein MS, et al: Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318-1322, 1980.
114. Mannucci PM, Remizzi C, Pusineri F, et al: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8-12, 1983.
115. Vigano G, Gaspari F, Locatelli M: Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 34(6):853-858, 1988.
116. Ahr DJ, Scialla SJ, Kimball DB Jr: Acquired platelet dysfunction following mithramycin therapy. Cancer 41:448-454, 1978.
117. Hicsonmez G, Buyukpamuken M: Effect of cancer chemotherapy drugs on platelet aggregation in children. Acta Haematol 58:312, 1977.
118. Pogliani EM, Fantasia R, Lambertenghi-Deliliers G, et al: Daunorubicin and platelet function. Thromb Haemost 45:36, 1981.
119. Shattil SJ, Bennett JS, McDonough M, et al: Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 65:329-337, 1980.
120. Brown CH III, Natelson EA, Bradshaw MW, et al: Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother 7:652-657, 1975.
121. Natelson EA, Brown CH, Bradshaw MW: Influence of cephalosporin antibiotics on blood coagulation and platelet function. Antimicrob Agents Chemother 9:91-93, 1976.
122. Kempin SJ, Jackson CW, Edwards CC: In vitro inhibition of platelet function and coagulation by pentamidine isethionate. Antimicrob Agents Chemother 12:451-454, 1977.
123. Davis R, Theologides A, Kennedy BJ: Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant disease. Ann Intern Med 71:67-80, 1969.
124. Sun NC, McAfee WM, Hum GJ, et al: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 71:10-16, 1979.
125. Kies MS, Posch JJ Jr, Ciolma JP, et al: Hemostatic function in cancer patients. Cancer 46:831-837, 1980.
126. Edwards RL, Rickles FR: Hemostatic alterations in cancer patients. In: Hemostatic Mechanisms and Metastasis, edited by KV Honn and B Sloane, Boston, Martinus Nijhoff, 1984, pp 342-354.
127. Sack GH Jr, Levin J, Bell WR, et al: Trousseau's syndrome and other manifestations of disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic and therapeutic features. Medicine (Baltimore) 56(1):1-37, 1977.
128. Rahr HB, Sorensen JV: Venous thromboembolism and cancer. Blood Coag Fibr 3:451-460, 1992.
129. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62:14-31, 1983.
130. Sawaya R, Kornblith PL: Brain tumors and thromboembolic complications. Surg Neurol 28(2):163, 1987.
131. Slichter SJ, Harker LA: Hemostasis in malignancy. Ann NY Acad Sci 230:252-261, 1974.
132. Prandori P, Lensing AWA, Büller HR, et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133, 1992.
133. Ambrus JL, Ambrus CM, Pickren JW: Causes of death in cancer patients. J Med 6:61-64, 1975.
134. Hedderich GS, O'Connor RJ, Reid ED, et al: Caval tumor thrombosis complicating renal cell carcinoma: A surgical challenge. Surgery 102:614-619, 1992.
135. Shattil SS: Diagnosis and treatment of recurrent venous thromboembolism. Med Clin North Am 68:577-600, 1984.
136. Miller SP, Sanchez-Avalos J, Stefanski T: Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 20:1452-1465, 1967.
137. Amundsen MA, Spitell JA, Thompson JH: Hypercoagulability associated with malignant disease and with the postoperative state. Ann Intern Med 58:608-616, 1963.
138. Falanga A, Ofosu FA, Delaini F, et al: The hypercoagulable state in cancer patients: Evidence for impaired thrombin inhibitions. Blood Coag Fibr 5(Suppl 1):519-523, 1994.
139. Bastida E, Ordinas A: Platelet contribution to the formation of metastatic foci: The role of cancer cell induced platelet activation. Haemostasis 18:29-36, 1988.
140. Rifkin DB, Loeb JN, Moore G, et al: Properties of plasminogen activators formed by neoplastic human cell cultures. J Exp Med 139:1317-1328, 1974.
141. Dvorak HF, Quay SC, Orenstein NS, et al: Tumor shedding and coagulation. Science 212:923, 1981.
142. Edgington TS: Activation of the coagulation system in association with neoplasia. J Lab Clin Med 96:1-4, 1980.
143. Dover R, Goeting NL, Taylor L, et al: Factor X activating actively in patients with colorectal carcinoma. Br J Surg 74:1122-1124, 1987.
144. el-Baruni K, Taylor I, Roath S, et al: Factor X-activating procoagulant in normal and malignant breast tissue. Hematol Oncol 8:323-332, 1990.
145. Andoh K, Kubota T, Takada M, et al: Tissue factor activity in leukemia cells: Special reference to disseminated intravascular coagulation. Cancer 59:748-754, 1987.
146. Goualt-Heilman M, Chardon E, Sultan C, et al: The procoagulant factor of leukaemia promyelocytes: Demonstration of immunologic cross-reactivity with human brain tissue factor. Br J Haematol 30:151-158, 1975.
147. Gralnick HR, Bagley J, Abrell E: Heparin treatment for the hemorrhagic diathesis of acute promyelocyte leukemia. Am J Med 52:167-174, 1972.
148. Gralnick HR, Sultan C: Acute promyelocytie leukemia: Haemorrhagic manifestations and morphologic criteria. Br J Haematol 29:333-336, 1975.
149. Bauer KA, Rosenberg RD: Thrombin generation in acute promyelocytic leukemia. Blood 64:791-796, 1984.
150. Polliack A: Acute promyelocytic leukemia with disseminated intravascular coagulation. Am J Clin Pathol 56:155-161, 1971.
151. Bennett B, Booth NA, Cruli A, et al: The bleeding disorder in acute promyelocytic leukemia: Fibrinolysis due to U-PA rather than defibrination. Br J Haematol 71:511-517, 1989.
152. Steerenberg L, Haak HL, Brommer EJP, et al: Evidence of fibrinogen breakdown by leucocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 15:126-133, 1985.
153. Gralnick HR, Marchesi S, Giveller H: Intravascular coagulation in acute leukemia: Clinical and subclinical abnormalities. Blood 40:709-718, 1972.
154. Tallman MS, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79:543-553, 1992.
155. Drapkin RL, Gee TS, Dowling MD, et al: Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 41:2484-2490, 1978.
156. Schwartz BS, Williams EC, Conlan MG, et al: Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2 plasmin inhibitor deficiency. Ann Intern Med 105:873-877, 1986.
157. Goldberg MA, Ginsburg D, Mayer RJ, et al: Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 69:187-191, 1987.
158. Rodeghiero F, Avvisali G, Castaman G, et al: Early deaths and antihemorrhagic treatment in acute promyelocytic leukemia: A GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112-2117, 1990.
159. Warrell RP Jr, Frankel SR, Miller WH, et al: Differentiation therapy of acute promyelocytie leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385-1393, 1991.
160. Sarris AH, Kempin S, Berman E, et al: High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 79:1305-1310, 1992.
161. Allessio MG, Falanga A, Consonni R, et al: Cancer procoagulant in acute lymphoblastic leukemia. Eur J Haematol 45:78-81, 1990.
162. Tsokos GC, Balow JE, Spiegel RJ, et al: Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 60:218-229, 1981.
163. Zusman J, Brown DM, Nesbit ME: Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 289:1335-1340, 1973.
164. Falanga A, Gordon SG: Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Biochemistry 24:5558-5567, 1985.
165. Gordon SG, Franks JJ, Lewis BJ: Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 62:773-776, 1979.
166. Gordon SG, Cross BA: An enzyme-linked immunoabsorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 50:6229-6234, 1990.
167. Pineo GF, Regoeczi E, Hatton MW, et al: The activation of coagulation by extracts of mucus: A possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 82:255-266, 1973.
168. Carson SD, Johnson DR: Consecutive enzyme cascades: Complement activation of the cell surface triggers increased tissue factor activity. Blood 76:361-367, 1990.
169. Valentino LA, Ladisch S: Circulating tumor gangliosides enhance platelet activation. Blood 83:2872-2877, 1994.
170. Lindahl AK, Sandset PM, Abildgaard V: The present status of tissue factor pathway inhibitors. Blood Coag Fibr 3:439-449, 1992.
171. Cohen JR, Tenenbaum N, Citron M: Greenfeld filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 109:12-15, 1991.
172. Calligaro KD, Bergen WS, Haut MJ, et al: Thromboembolic complications in patients with advanced cancer: Anticoagulation versus Greenfield filter placement. Ann Vasc Surg 5:186-189, 1991.
173. Levine M, Hirsh J, Gent M, et al: Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889, 1994.
174. Brain MC, Dacie JV, Hourihane O'B: Microangiopathic hemolytic anaemia: The possible role of vascular lesions in pathogenesis. Br J Haematol 8:358-374, 1962.
175. Antman KH, Skarin AT, Mayer RJ, et al: Microangiopathic hemolytic anemia and cancer. A review. Medicine (Baltimore) 58:377-384, 1979.
176. Cohan M, Pittman G, Hoffman CC: Hemolytic anemia, tumor cell emboli and intravascular coagulation. Arch Pathol 93:305-307, 1972.
177. Rogers L, Cho E, Kempin S, et al: Cerebral infarction from non-bacterial thrombotic endocarditis. Am J Med 80:746-756, 1987.
178. Sigsbee B, Deck MDF, Posner JB: Non-metastatic superior sagittal sinus thrombosis complicating systemic cancer. Neurology 29:139-146, 1979.
179. Ghosh L, Muehrcke RC: The nephrotic syndrome: A prodrome to lymphoma. Ann Intern Med 72:379-382, 1970.
180. Corrigan JJ Jr, Ray WL, May N: Changes in the blood coagulation system associated with septicemia. N Engl J Med 279:851-856, 1968.
181. Bisno Al, Freeman JC: The syndrome of asplenia, pneumococcal sepsis, and disseminated intravascular coagulation. Ann Intern Med 72:389-393, 1970.
182. Corrigan JJ Jr: Heparin therapy in bacteremic septicemia. J Pediatr 91:695-700, 1977.
183. Man MJ, King EG: Severe acute disseminated intravascular coagulation: A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am J Med 67:557-563, 1979.
184. Blanchard RA, Furie BC, Jorgensen M, et al: Acquired vitamin K dependent carboxylation deficiency in liver disease. N Engl J Med 305:242-248, 1981.
185. Lane DA, Scully MF, Thomas DP, et al: Acquired dysfibrinogenemia in acute and chronic liver disease. Br J Haematol 35:301-308, 1971.
186. Isaacson P, Wright DR: Intestinal lymphoma associated with malabsorption. Lancet 1:67-70, 1978.
187. Ansell JE, Kumar R, Deykin D: The spectrum of vitamin K deficiency. JAMA 238:40-42, 1977.
188. Uotila L, Suttie JW: Inhibition of vitamin K-dependent carboxylase in vitro by cefamandole and its structural analogs. J Infect Dis 148:571-578, 1983.
189. Barza M, Furie B, Brown AE, et al: Defects in vitamin K dependent carboxylation associated with moxalactam treatment. J Infect Dis 153:1166-1169, 1986.
190. Lipsky JJ: Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole containing antibiotics. Proc Natl Acad Sci USA 81:2893-2897, 1984.
191. Bang NU, Tessler SS, Heidereich RO, et al: Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis 4(Suppl 5):546-554, 1982.
192. Monto RW, Talley RW, Caldwell MJ, et al. Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC 24554) therapy. Cancer Res 29:697-704, 1969.
193. Gralnick HR, Henderson E: Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer 27:1313-1320, 1970.
194. Kucuk O, Kwaan HC, Gunnar W, et al: Thromboembolic complications associated with L-asparaginase therapy. Cancer 55:702-706, 1985.
195. Hasegawa DK, Bennett AJ, Coccia PF, et al: Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood 56:585-595, 1980.
196. Waddell CC, Brown JA, Udden MM: Plasma prekallikrein (Fletcher factor) deficiency in a patient with chronic lymphocytic leukemia. South Med J 73:1653-1655, 1980.
197. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984.
198. Coleman M, Vigliano EM, Weksler ME, et al: Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood 39:210-223, 1972.
199. MacKenzie MR, Fudenbcrg RR: Macroglobulinemia: Analysis of forty patients. Blood 39:874-889, 1972.
200. Dorimenc J, Prest RJ, Samama M, et al: Anomalie de l'aggregation plaquettaire au cours de la maladie de Waldenström (a propos 3 cas). Nouv Rev Fr Haematol 6:734, 1966.
201. Kaufman PA, Gockerman JP, Greenberg CS: Production of a novel anticoagulant by neoplastic plasma cells and report of a case and review of the literature. Am J Med 86:612-616, 1989.
202. Harbaugh ME, Hill EM, Corin RB: Antithrombin and antithromboplastin activity accompanying IgG myeloma: Report of a case with a severe bleeding tendency. Am J Clin Pathol 63:57-67, 1975.
203. Stein CA, Larocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989.
204. Glueck HI, Hong R: A circulating anticoagulant in Ig1 A-multiple myeloma: Its modification by penicillin. J Clin Invest 44:1866-1881, 1965.
205. Zettervall O, Nilsson IM: Acquired von Willebrand's disease caused by a monoclonal antibody. Acta Med Scand 204:521-528, 1978.
206. Thiagarajan P, Shapiro SS, Demarco L: Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity: Mechanism of a lupus anticoagulant. J Clin Invest 66:397-405, 1980.
207. Astedt B, Holmberg L: Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261:595-597, 1976.
208. Walker W, Laforet EG: Hemorrhage from fibrinolysis in pulmonary surgery: Report of a case with study of the coagulation mechanism. J Thorac Surg 32:548-554, 1956.
209. Welbom JK, Brennan MJ, Rathaway JG Jr: Acute fatal fibrinolysis with gastric carcinoma. Am J Surg 108:344-348, 1964.
210. Ratnoff OD: Studies on a proteolytic enzyme in human plasma. VII. A fatal hemorrhagic state associated with excessive plasma proteolytic activity in a patient undergoing surgery for carcinoma of the head of the pancreas. J Clin Invest 31:521-528, 1952.
211. Pellman CM, Ridlon HC, Phillips LL: Manifestations and management of
212. Zacharski LR, Henderson WG, Rickles FR, et al: Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 245:831-835, 1981.
213. Temple WJ, Ketcham AS: Current clinical trials with anticoagulant therapy in the management of cancer patients. In: Hemostatic Mechanisms and Metastasis, edited by KV Honn, BF Sloane, Boston, Martinus Nijhoff, 1994, pp 409-425.